☆ 4.6 Article

Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein

MOVEMENT DISORDERS (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?

Simone Engelender et al.

Summary: Neurodegenerative proteinopathies are a class of neurodegenerative disorders characterized by the accumulation of abnormal protein deposits. Stimulating protein degradation pathways may be a potential therapeutic strategy, but there are gaps and controversies in both experimental and clinical studies.

MOVEMENT DISORDERS (2022)

Add to Collection

Article Neurosciences

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments

Matthew E. Gegg et al.

Summary: Dysfunction of the endolysosomal system is associated with the pathogenesis of Parkinson's disease (PD), and genetic variants in the GBA gene are a common risk factor. GCase deficiency in neurons and glia may contribute to PD by promoting the accumulation and spread of alpha-synuclein aggregates. Dysregulation of lipids, including sphingolipids, phospholipids, and cholesterol, as well as neuroinflammation and the interaction between GCase and LRRK2 protein, are also implicated in PD pathogenesis.

NEUROBIOLOGY OF DISEASE (2022)

Add to Collection

Article Medicine, General & Internal

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind placebo-controlled phase 1a trial

Johannes Levin et al.

Summary: This study evaluated the safety and pharmacokinetics of an orally bioavailable compound anle138b in healthy subjects through a single ascending dose (SAD) and multiple ascending dose (MAD) study. The results showed that anle138b did not cause major adverse events at doses that achieved therapeutic exposure levels in a mouse Parkinson model. These findings suggest the need for further clinical trials of anle138b in patients with synucleinopathies.

EBIOMEDICINE (2022)

Add to Collection

Article Clinical Neurology

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

Johan Willem Smit et al.

Summary: This study investigated the safety, tolerability, and pharmacokinetics of UCB0599 in both healthy participants and participants with Parkinson's disease (PD). The results demonstrated that UCB0599 had rapid absorption and predictable pharmacokinetic properties, with no significant food effect observed. Co-administration with itraconazole affected the disposition of UCB0599, but did not impact its safety profile. Treatment-related adverse events were more common in PD patients receiving UCB0599, but were mostly mild to moderate in intensity and unrelated to dosage.

MOVEMENT DISORDERS (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Monoclonal Antibody Therapy in Parkinson's Disease - The End?

Alan Whone

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trial of Prasinezumab in Early-Stage Parkinson's Disease

G. Pagano et al.

Summary: The study found that prasinezumab had no meaningful effect on global or imaging measures of Parkinson's disease progression and was associated with infusion reactions.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trial of Cinpanemab in Early Parkinson's Disease

A. E. Lang et al.

Summary: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Structures of α-synuclein filaments from human brains with Lewy pathology

Yang Yang et al.

Summary: Parkinson's disease (PD) is a common movement disorder characterized by resting tremor, rigidity, bradykinesia and postural instability. It is associated with the presence of alpha-synuclein inclusions in brain cells. Many PD patients develop dementia after several years of diagnosis. PD dementia (PDD) is similar to dementia with Lewy bodies (DLB), which is diagnosed when cognitive impairment precedes parkinsonian motor signs or begins within one year from their onset.

NATURE (2022)

Add to Collection

Article Clinical Neurology

Disease-Associated a-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

Nour Majbour et al.

Summary: This study demonstrated the quantification of aSyn aggregates in PD patients through a combination of seed amplification assay and ELISA, showing that this method is more effective than using SAA alone and can reflect the disease stage of patients.

NEUROLOGY (2022)

Add to Collection

Article Neurosciences

Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease

Hiroaki Sekiya et al.

Summary: The distribution of alpha SYN oligomers differs from Lewy-related pathology (LRP) in Parkinson's disease (PD), with alpha SYN oligomer burden being significantly greater in the neocortex and LRP being greater in vulnerable subcortical regions. In addition, alpha SYN oligomers in the hippocampus are associated with cognitive impairment in PD.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)

Add to Collection

Article Clinical Neurology

Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study

Johannes Attems et al.

Summary: Several staging systems exist for the neuropathological diagnosis of LBD, with varying levels of inter-rater reliability. The LPC system, based on a dichotomous approach for scoring LP, showed good reproducibility and allowed for the classification of all cases into distinct categories. It may serve as a reliable and useful standard future approach for the post-mortem evaluation of LP.

ACTA NEUROPATHOLOGICA (2021)

Add to Collection

Article Medicine, Research & Experimental

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease

Tracy A. Cole et al.

Summary: Research has shown that antisense oligonucleotides (ASOs) reduce the production of aSyn in PD models, leading to prevention and removal of established aSyn pathology, and preventing dopaminergic cell dysfunction. The translational potential of this approach has been demonstrated in nonhuman primates, suggesting that inhibiting aSyn production could potentially reverse established pathology and serve as a disease-modifying therapy for PD and related synucleinopathies.

JCI INSIGHT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques

Diego Sucunza et al.

Summary: Mutations in the GBA1 gene are the main genetic risk factor for Parkinson's disease, and enhancing GCase activity can reduce alpha-synuclein burden and prevent dopaminergic cell death. Gene therapy targeting GCase can improve survival of dopaminergic neurons and serve as a disease-modifying treatment for PD and related synucleinopathies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Neurosciences

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease

Marco J. Russo et al.

Summary: Alpha Synuclein seed amplification assays (Alpha Syn-SAAs) are considered promising diagnostic tools for Parkinson's disease and related synucleinopathies, showing high diagnostic accuracy in multiple patient cohorts. This study compared results from three independent laboratories and found high reproducibility and diagnostic performance of the assay.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)

Add to Collection

Article Clinical Neurology

The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy

Tim E. Moors et al.

Summary: Research has shown that various post-translationally modified proteoforms of alpha-synuclein accumulate in Lewy bodies in different regions of the Parkinson's disease brain, providing insights into the orchestration of Lewy pathology. High-resolution and 3D multicolor microscopy in post-mortem human brain tissues offer potential mechanisms underlying a regulated Lewy body morphogenesis.

ACTA NEUROPATHOLOGICA (2021)

Add to Collection

Article Neurosciences

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Werner Poewe et al.

Summary: This phase 1 study evaluated the safety and tolerability of PD03A in patients with early Parkinson's disease, with all patients experiencing at least one adverse event. A substantial IgG antibody response against PD03 was observed, reaching maximum titers at Week 12. The differences in titers between the active groups and placebo were statistically significant from the second immunization at Week 8 until Week 52, supporting the further development of active immunotherapeutic approaches for PD treatment.

JOURNAL OF PARKINSONS DISEASE (2021)

Add to Collection

Review Neurosciences

Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease

Luis M. A. Oliveira et al.

Summary: The authors aim to summarize critical features of alpha-synuclein and identify knowledge gaps in PD research to propose future research directions. Their goal is to develop therapies that can slow or stop the progression of PD.

NPJ PARKINSONS DISEASE (2021)

Add to Collection

Article Geriatrics & Gerontology

Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice

Natalia Ninkina et al.

NEUROBIOLOGY OF AGING (2020)

Add to Collection

Article Pharmacology & Pharmacy

Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

Mita Kuchimanchi et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)

Add to Collection

Article Neurosciences

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models

Andreas Weihofen et al.

NEUROBIOLOGY OF DISEASE (2019)

Add to Collection

Article Clinical Neurology

Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054

Miroslaw Brys et al.

MOVEMENT DISORDERS (2019)

Add to Collection

Article Neurosciences

Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes

Sarah H. Shahmoradian et al.

NATURE NEUROSCIENCE (2019)

Add to Collection

Article Clinical Neurology

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes

Yaping Chu et al.

BRAIN (2019)

Add to Collection

Article Multidisciplinary Sciences

Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts

Timo Strohaeker et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Medicine, Research & Experimental

Genetics of Synucleinopathies

Robert L. Nussbaum

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

Add to Collection

Article Clinical Neurology

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

John L. Robinson et al.

BRAIN (2018)

Add to Collection

Article Clinical Neurology

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial

Joseph Jankovic et al.

JAMA NEUROLOGY (2018)

Add to Collection

Article Neurosciences

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity

Matthew J. Benskey et al.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)

Add to Collection

Article Clinical Neurology

First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers

Dale B. Schenk et al.

MOVEMENT DISORDERS (2017)

Add to Collection

Article Clinical Neurology

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects

Julianna J. Tomlinson et al.

JOURNAL OF NEURAL TRANSMISSION (2017)

Add to Collection

Article Medicine, General & Internal

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

Beverley J. Shea et al.

BMJ-BRITISH MEDICAL JOURNAL (2017)

Add to Collection

Article Medicine, General & Internal

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

Beverley J. Shea et al.

BMJ-BRITISH MEDICAL JOURNAL (2017)

Add to Collection

Article Clinical Neurology

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain

Rosalind F. Roberts et al.

BRAIN (2015)

Add to Collection

Article Neurosciences

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

Dora Games et al.

JOURNAL OF NEUROSCIENCE (2014)

Add to Collection

Article Clinical Neurology

Acid β-Glucosidase Mutants Linked to Gaucher Disease, Parkinson Disease, and Lewy Body Dementia Alter α-Synuclein Processing

Valerie Cullen et al.

ANNALS OF NEUROLOGY (2011)

Add to Collection

Article Neurosciences

α-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies

Youngshin Lim et al.

JOURNAL OF NEUROSCIENCE (2011)

Add to Collection

Article Multidisciplinary Sciences

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

Eliezer Masliah et al.

PLOS ONE (2011)

Add to Collection

Review Medicine, Research & Experimental

Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies

Brit Mollenhauer et al.

BIOMARKERS IN MEDICINE (2010)

Add to Collection

Article Medicine, General & Internal

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

E. Sidransky et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells

Tereza Vogiatzi et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2008)

Add to Collection

Article Multidisciplinary Sciences

GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein

Clemens R. Scherzer et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Add to Collection

Article Neurosciences

Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies

Michael L. Kramer et al.

JOURNAL OF NEUROSCIENCE (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.